NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)

Anaplastic thyroid cancer (ATC) is an almost invariable lethal cancer in humans. Most patients present with a rapid progressive mass in the neck with progressive complaints like dyspnoea, dysphagia or pain. The risk of suffocation is the main reason for rapid surgical intervention, but we know from literature that an oncological resection with clear margins is seldomly achieved. Some patients deteriorate that fast after surgery that radiation therapy and/or chemotherapy is not feasible anymore. Patients with BRAF-mutated ATC already have shown to benefit from targeted BRAF/MEK inhibition. Thi

Trial Details

NCT ID

NCT06079333

Phase

PHASE2

Sponsor

Leiden University Medical Center

Status

RECRUITING

Cancer Type

Thyroid Cancer

Interventions

• dabrafenib/trametinib

Locations (sample)

• Leiden, South Holland, Netherlands|52.15833,4.49306

Key Eligibility Criteria

• Informed consent.
• Age over 18 years old.
• World Health Organization (WHO) Performance Status 0 or I.
• Histologically confirmed ATC (centrally reviewed).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Thyroid Cancer Trials on Trialify →